Results 81 to 90 of about 24,787 (310)

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab

Respiratory Medicine Case Reports
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic
Daiki Nakashima, Eri Mori, Nobuyoshi Otori   +2 more
doaj   +1 more source

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Katsaounou, Paraskevi, Martinez, Rafael, Pfister, Pascal, Wahn, Ulrich   +6 more
core   +1 more source

Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. [PDF]

, 2017
IgE and not IgG is usually associated with allergy. IgE lodged on mast cells in skin or gut and basophils in the blood allows for the prolonged duration of allergy through the persistent expression of high affinity IgE receptors.
Amlot P. L., Concha L. B., Delves P. J., Edkins A., Finkelman F. D., Hazenbos W. L., Huizinga T. W., Lessof M. H., Mauro M., McConnell T. H., McMenamin C., Mosmann T. R., Palmeira P., Platts‐Mills T. A., Ren R., Schandane L., Tiseo P. J., Van Der Zee J. S., Yang F.   +18 more
core   +2 more sources

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Dupilumab in the treatment of severe non-control broncial asthma — economic aspects

Качественная клиническая практика, 2019
Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods.
A. S. Salasyuk, M. Yu. Frolov, I. N. Barykina   +2 more
doaj   +1 more source

Group 2 Innate Lymphoid Cells in Respiratory Allergic Inflammation [PDF]

, 2019
Millions of people worldwide are suffering from allergic inflammatory airway disorders. These conditions are regarded as a consequence of multiple imbalanced immune events resulting in an inadequate response with the exact underlying mechanisms still ...
Duerr, Claudia U., Fritz, Jörg H., Helfrich, Sofia, Mindt, Barbara C.   +3 more
core   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study

Allergology International
Background: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension
Yoko Kataoka, Motohiro Ebisawa, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal, Kenji Yahata   +12 more
doaj   +1 more source

The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Drug Design, Development and Therapy, 2023
Sarah Balboul,1 Julia Kahn,1 Alexis Tracy,2 Anjelica Peacock,3 Abigail Cline2– 4 1School of Medicine, New York Medical College, Valhalla, NY, USA; 2Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3Department of Dermatology ...
Balboul S, Kahn J, Tracy A, Peacock A, Cline A   +4 more
doaj  

41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers [PDF]

, 2023
Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Amy Praestgaard, Randy Prescilla, Zhixiao Wang, Ainara Rodríguez Marco   +9 more
openalex   +1 more source